Andrew P. Feinberg is the Bloomberg Distinguished Professor of Epigenetics, King Fahd Professor of Medicine, Biomedical Engineering, Oncology, Molecular Biology & Genetics, Psychiatry & Behavioral Sciences, Biostatistics, and Mental Health at Johns Hopkins University. He serves as Director of the Center for Epigenetics in the Institute for Basic Biomedical Sciences and Chief of the Division of Molecular Medicine in the Department of Medicine. Feinberg earned his BA in Biology in 1973, MD in 1976 from the accelerated medical program, and MPH in 1981, all from Johns Hopkins University. He completed a postdoctoral fellowship in developmental biology at the University of California, San Diego, clinical training in medicine at the University of Pennsylvania, and genetics research and clinical training at Johns Hopkins. Appointed as an assistant professor at Johns Hopkins in 1983, he later served as a Howard Hughes Medical Investigator at the University of Michigan before returning in 1994 as the King Fahd Professor. Named an inaugural Gilman Scholar in 2011 and Bloomberg Distinguished Professor in 2015 across the Schools of Medicine, Engineering, and Public Health, he holds joint appointments in Molecular Biology & Genetics, Oncology, Psychiatry & Behavioral Sciences, and Genetic Medicine.

Feinberg is recognized as the founder of cancer epigenetics, having discovered altered DNA methylation in cancer in the early 1980s with Bert Vogelstein, identified loss of imprinting of IGF2 in tumors, and provided evidence for the epigenetic hypothesis of cancer through studies on Beckwith-Wiedemann syndrome. He pioneered epigenomics by establishing the first NIH-supported Epigenome Center, developing tools for genome-scale analysis, and mapping methylomes in hematopoietic development and iPSC reprogramming. His research explores epigenetic mechanisms in cancer progression, aging, neuropsychiatric diseases like schizophrenia, environmental interactions, stochastic epigenetic plasticity, and epigenetic inheritance, including contributions to NASA's Twins Study on spaceflight effects. Key publications include "The key role of epigenetics in human disease prevention and mitigation" (New England Journal of Medicine, 2018), "Large-scale epigenomic reprogramming links anabolic glucose metabolism to distant metastasis during the evolution of pancreatic cancer progression" (Nature Genetics, 2017), "Neuronal brain region-specific DNA methylation and chromatin accessibility are associated with neuropsychiatric disease heritability" (Nature Neuroscience, 2019), and "Potential energy landscapes identify the information-theoretic nature of the epigenome" (Nature Genetics, 2017). He has received the Harvey Prize (2022-23), NIH Director's Pioneer Award (2011), Feodor Lynen Medal, honorary doctorates from Karolinska Institutet (2010), Uppsala University (2007), and University of Amsterdam (2016), and is a member of the National Academy of Medicine (2007), Fellow of the American Academy of Arts and Sciences, and American Association for the Advancement of Science. Feinberg has served as associate editor for Cancer Research, American Journal of Human Genetics, and Cancer Cell, and contributed to the NIH Epigenetics Roadmap Initiative and International Human Epigenome Consortium.

Professional Email: afeinberg@jhu.edu